Three oncofusions are included in the favorable risk subgroup of AML: PML::RARA AML is characterized by a fusion between PML, a nuclear protein with a variety of functions, and retinoic acid receptor α (RARA), a nuclear receptor and transcription factor (4–7). The gene discussed is PML; the disease is acute myeloid leukemia.